Detalhe da pesquisa
1.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153814
2.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343151
3.
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Clin Infect Dis
; 77(2): 280-286, 2023 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36976301
4.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
5.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
6.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363892
7.
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product.
J Transl Med
; 20(1): 14, 2022 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986854
8.
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.
Haematologica
; 107(6): 1410-1426, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670358
9.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794557
10.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222197
11.
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Hematol Oncol
; 39(3): 409-418, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33590502
12.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860137
13.
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.
Haematologica
; 105(10): 2420-2431, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054082
14.
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Hematol Oncol
; 38(3): 372-380, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271957
15.
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Hematol Oncol
; 37(4): 418-423, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985017
16.
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Ann Hematol
; 98(4): 889-896, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30515542
17.
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Br J Haematol
; 183(1): 35-46, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30010187
18.
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.
Blood
; 127(9): 1138-50, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26675349
19.
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
Haematologica
; 103(1): 80-90, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29025907
20.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Hematol Oncol
; 2018 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29624703